Ctim-03. Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare Cns Cancers: Results of Interim Analysis in a Non-heavily Pretreated Cohort
Year: 2024
Type: conference-abstract
Abstract: BACKGROUND There is a paucity of salvage therapies for patients with rare CNS tumors. Nivolumab (PD-1 inhibitor) is approved for a variety of systemic cancers. We developed a multisite basket Phase II trial to evaluate Nivolumab for patients with recurrence of one of 12 selected rare CNS cancers. Efficacy is measured by Disease Control Rate (DCR; confirmed CR/PR or durable SD for ≥ 6 months) in 2 cohorts: heavily and non-heavily pretreated (≥ 3 prior therapies, vs. ≤ 2; including radiation and/or standard or experimental drugs). Cohort 1 has been completed. We report efficacy results and safety data of a preplanned interim analysis in Cohort 2 (non-heavily pretreated). METHODS In addition to progressive disease, eligibility includes available tumor tissue; age ≥ 18; KPS ≥ 70; no steroids at trial entry. Planned accrual: 75 in each cohort. Nivolumab dose: 240 mg IV every 2 weeks (4 doses), followed by 480 mg every 4 weeks (14 additional doses). Interim analysis was planned when the sample size reached 32 in each cohort. RESULTS As of December 1, 2023, among 27 evaluable patients treated in the non-heavily pretreated cohort, 10 achieved SD ≥ 6 months (DCR 37%; 95% CI 19.4%,57.6%) – 6 high-grade meningiomas; 1 each: myxopapillary ependymoma with lung metastases; solitary fibrous tumor, gliomatosis (astrocytoma IDH mutant WHO grade 2), chordoma. A total of 56 Grade 3-5 AEs occurred; 13 (Grade 3-4) related to nivolumab, including Grade 3 gait disturbance (3); cerebral edema, cognitive disturbance, colitis, headache, hypotension, hypoxia, lymphopenia, pain, and pruritus (1 each), and one Grade 4 cerebral edema. The three Grade 5 AEs were disease-related. CONCLUSION Preliminary efficacy analysis exceeded the “go” boundary (i.e., > 5 responders) in the non-heavily pretreated cohort. Nivolumab showed an acceptable safety profile. Cohort 2 will continue to complete a planned accrual of 75 patients.
Source: Neuro-Oncology
Authors: Lorenzo Argao, Ying Yuan, Kathleen Wall, Tricia Kunst, Claudia Chambers, Elizabeth Vera, Caitlin Huguely, Masashi Watanabe, Ewa Grajkowska, Zied Abdullaev, Alvina Acquaye-Mallory, Kenneth Aldape, Brita Anderson, Lisa Boris, Daniela A Bota, Nicole Briceno, Eric Burton, Anna Choi, P J Cimino, Pierre Giglio, Carlos Kamiya-Matsuoka, Priya U Kumthekar, Jason Levine, Scott M Lindhorst, Byram Ozer, Marissa Panzer, Tina Pillai, Lily Polskin, Drew Pratt, Martha Quezado, Renee Tweneboah-Koduah, Jing Wu, Terri S Armstrong, Mark R Gilbert, Marta Penas-Prado
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4404230920